PMID- 25196083
OWN - NLM
STAT- MEDLINE
DCOM- 20151005
LR  - 20220409
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 13
IP  - 10
DP  - 2014 Oct
TI  - 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
PG  - 1407-22
LID - 10.1517/14740338.2014.954546 [doi]
AB  - INTRODUCTION: 5-Hydroxytryptamine3-receptor antagonists (5-HT3-RA) are the most 
      widely used antiemetics in oncology, and although tolerability is high, QTC 
      prolongation has been observed in some patients. AREAS COVERED: The purpose of 
      this article is to outline the risk of cardiac adverse events (AEs) from 
      5-HT3-RAs, with focus on the three most commonly used, ondansetron, granisetron 
      and palonosetron. EXPERT OPINION: Most of the studies analyze electrocardiogram 
      (ECG) changes after 5-HT3-RA administrations in healthy, young adults, or in 
      noncancer patients to treat postoperative nausea and vomiting (PONV). Only a few 
      studies have addressed ECG changes in cancer patients treated for 
      chemotherapy-induced nausea and vomiting (CINV). Investigations in cancer 
      patients are essential, because these patients are older and have a higher 
      incidence of comorbidity, than those usually included in clinical trials. 
      Furthermore, polypharmacy is frequent and drug-drug interactions between 
      chemotherapy and other QTc-prolonging drugs may influence the pharmacokinetics 
      and pharmacodynamics of the 5-HT3-RAs. During the next 10 - 15 years a huge 
      increase in the number of cancer patients is expected, primarily in the group of 
      65-plus-year old. Therefore it will be crucial to address the incidence of 
      cardiac AEs in cancer patients with known heart disease receiving chemotherapy 
      and a 5-HT3 RA for the prophylaxis of CINV.
FAU - Brygger, Louise
AU  - Brygger L
AD  - Odense University Hospital, Department of Oncology R , Odense , Denmark.
FAU - Herrstedt, Jorn
AU  - Herrstedt J
CN  - Academy of Geriatric Cancer Research (AgeCare)
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140906
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antiemetics)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Isoquinolines)
RN  - 0 (Quinuclidines)
RN  - 0 (Serotonin 5-HT3 Receptor Antagonists)
RN  - 4AF302ESOS (Ondansetron)
RN  - 5D06587D6R (Palonosetron)
RN  - WZG3J2MCOL (Granisetron)
SB  - IM
MH  - Aged
MH  - Antiemetics/*adverse effects/therapeutic use
MH  - Antineoplastic Agents/adverse effects
MH  - Cardiovascular Diseases/*chemically induced/epidemiology
MH  - Granisetron/adverse effects/therapeutic use
MH  - Humans
MH  - Isoquinolines/adverse effects/therapeutic use
MH  - Long QT Syndrome/chemically induced/epidemiology
MH  - Nausea/chemically induced/prevention & control
MH  - Neoplasms/drug therapy
MH  - Ondansetron/adverse effects/therapeutic use
MH  - Palonosetron
MH  - Quinuclidines/adverse effects/therapeutic use
MH  - Serotonin 5-HT3 Receptor Antagonists/*adverse effects/therapeutic use
MH  - Vomiting/chemically induced/prevention & control
OTO - NOTNLM
OT  - 5-Hydroxytryptamine3-receptor antagonist
OT  - QT prolongation
OT  - cardiac adverse events
OT  - cardiac side effects
OT  - granisetron
OT  - ondansetron
OT  - palonosetron
EDAT- 2014/09/10 06:00
MHDA- 2015/10/06 06:00
CRDT- 2014/09/09 06:00
PHST- 2014/09/09 06:00 [entrez]
PHST- 2014/09/10 06:00 [pubmed]
PHST- 2015/10/06 06:00 [medline]
AID - 10.1517/14740338.2014.954546 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2014 Oct;13(10):1407-22. doi: 10.1517/14740338.2014.954546. 
      Epub 2014 Sep 6.